Results 61 to 70 of about 3,296 (215)

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma

Cancer Reports, 2022
Background Survival for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. Aims To study the feasibility and safety of incorporating a genomic‐based targeted agent to induction therapy for HRNB as well as ...
Jacqueline M. Kraveka, Elizabeth C. Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld, Elizabeth Kim, Abhinav B. Nagulapally, Karl J. Dykema, Valerie I. Brown, William D. Roberts, Deanna Mitchell, Don Eslin, Derek Hanson, Michael S. Isakoff, Randal K. Wada, Virginia L. Harrod, Jawhar Rawwas, Gina Hanna, William P. D. Hendricks, Sara A. Byron, Matija Snuderl, Jonathan Serrano, Jeffrey M. Trent, Giselle L. Saulnier Sholler   +23 more
doaj   +1 more source

Induction Regimens in High‐Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities

Cancer Medicine, Volume 14, Issue 22, November 2025.
ABSTRACT Background Numerous induction therapies have been evaluated for high‐risk neuroblastoma (HRNBL). It is not known how these regimens' response rates nor toxicities compare. We aimed to describe and compare key features of HRNBL induction regimens and their associations with study‐level end‐induction response (EIR).
Samantha D. Martin, Eva C. Robinson, Edie Weller, Rochelle Bagatell, Lucas Moreno, Steven G. DuBois   +5 more
wiley   +1 more source

Effects of Difluoromethylornithine Chemoprevention on Audiometry Thresholds and Otoacoustic Emissions [PDF]

, 2001
ObjectivesTo determine the effects of long-term, low-dose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans.DesignA prospective, randomized, placebo-controlled phase 2 clinical ...
Shanks, JE, McLaren, CE, Galus, CM, Meyskens, FL, Doyle, KJ   +4 more
core   +1 more source

Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?

Acta Ophthalmologica, Volume 103, Issue 7, Page e436-e455, November 2025.
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs, Berith M. Balfoort, Marion M. Brands, Anneloor L. M. A. ten Asbroek, Camiel J. F. Boon, Roselie M. H. Diederen, Corrie Timmer, Margreet A. E. M. Wagenmakers, Hans R. Waterham, Ronald J. A. Wanders, Riekelt H. Houtkooper, Clara D. van Karnebeek, Arthur A. Bergen   +12 more
wiley   +1 more source

Supplementary Figure S1 from Unbiased Metabolite Profiling Indicates That a Diminished Thymidine Pool Is the Underlying Mechanism of Colon Cancer Chemoprevention by Alpha-Difluoromethylornithine

, 2013
Supplementary Figure S1 - PDF file 174K, Fig S1. Technical reproducibility of LC-MS-based metabolite profiling in the HT-29 colorectal cancer cell line.
Qiuying Chen (157606), Mavee Witherspoon (14893746), Steven M. Lipkin (14873730), Steven S. Gross (157625), Levy Kopelovich (32912)   +4 more
core   +1 more source

Supplementary Figure S2 from Unbiased Metabolite Profiling Indicates That a Diminished Thymidine Pool Is the Underlying Mechanism of Colon Cancer Chemoprevention by Alpha-Difluoromethylornithine

, 2013
Supplementary Figure S2 - PDF file 19K, Fig.S2. DFMO triggers an increase in HT-29 cells of 5-methyltetrahydrofolate, the essential cofactor for support of methionine regeneration from homocysteine. Identification of 5-methyltetrahydrofolate was based on
Qiuying Chen (157606), Mavee Witherspoon (14893746), Steven M. Lipkin (14873730), Steven S. Gross (157625), Levy Kopelovich (32912)   +4 more
core   +1 more source

Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma

Frontiers in Oncology, 2012
Polyamines are highly regulated essential cations that are elevated in rapidly proliferating tissues, including diverse cancers. Expression analyses in neuroblastomas suggest that upregulation of polyamine pro-synthetic enzymes and downregulation of ...
Laura Dawn Gamble, Michael D Hogarty, Xuenyuan eLiu, David S Ziegler, David S Ziegler, Glenn M Marshall, Glenn M Marshall, Murray D Norris, Michelle eHaber   +8 more
doaj   +1 more source

Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy

Advanced Science, Volume 12, Issue 40, October 27, 2025.
Metabolic rewiring in cancer is mapped across glucose, amino acid, lipid, nucleotide, and mitochondrial pathways, with emphasis on immune regulation. The review integrates mechanisms linking these pathways to tumor progression and therapy resistance, and profiles nanomaterial platforms that both deliver therapeutics and actively reprogram ...
Xiaosu Zhou, Ruibing Deng, Zunde Liao, Xiaoyu Huang, Junting Huang, Hanlou Yang, Kam W. Leong, Yiling Zhong   +7 more
wiley   +1 more source

Polyamine depletion induces G₁ and S phase arrest in human retinoblastoma Y79 cells

Cancer Cell International, 2008
Background Polyamines and ornithine decarboxylase (ODC) are essential for cell proliferation. DL-α-difluoromethylornithine (DFMO), a synthetic inhibitor of ODC, induces G1 arrest through dephosphorylation of retinoblastoma protein (pRb).
Kubota Shunichiro, Araie Makoto, Ueda Akiko   +2 more
doaj   +1 more source

A Case of APC Gene Mutation‐Associated Familial Adenomatous Polyposis With Multiple System Malignancies

Cancer Reports, Volume 8, Issue 10, October 2025.
ABSTRACT Background Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disorder, with a nearly 100% risk of developing colorectal cancer by the age of 40. The primary gene mutated in FAP is APC, and mutations in certain regions of the APC gene may be associated with thyroid disorders, including malignant neoplasms, benign nodules ...
Ren Yijing, Wang Wenjun, Gao Xiang, Xing Kongling, Chen Yunxia, Liao Wei, Zhou Ping   +6 more
wiley   +1 more source